Introduction to the RAPID Consortium Findings

Adamantinomatous craniopharyngioma management remains a significant clinical challenge due to the tumor's invasive nature and proximity to vital brain structures. Historically, research on this rare tumor relied on small, single-center experiences. However, a new study from the Registry of Adenomas of the Pituitary and Related Disorders (RAPID) consortium provides high-powered data. This multicenter analysis tracked 359 patients across the United States to evaluate surgical success and long-term prognosis. Consequently, the findings offer a more generalizable framework for clinical decision-making.

Surgical Approaches and Resection Rates

Modern neurosurgical techniques have shifted toward minimally invasive procedures. Notably, 76% of patients in this cohort underwent endoscopic transsphenoidal surgery. In contrast, surgeons performed open craniotomies in only 22% of cases. Despite these advanced techniques, achieving complete tumor removal remains difficult. Surgeons achieved gross-total resection in 45% of patients, while 47% underwent subtotal resection. Therefore, clinicians must carefully balance aggressive removal with the preservation of surrounding neurological tissues.

Prognostic Factors in Adamantinomatous Craniopharyngioma Management

The study identified specific variables that predict tumor recurrence. Multivariable analysis revealed that subtotal or partial resection significantly worsened progression-free survival (PFS). Additionally, larger tumor size and extension beyond the sella region independently predicted poorer outcomes. Specifically, the PFS rate declined from 66% at one year to just 31% at six years. Because recurrence is common, long-term radiographic surveillance is essential for all postoperative patients. Furthermore, primary and salvage surgeries showed comparable survival benefits, suggesting that repeat intervention remains a viable option.

Managing Postoperative Endocrinopathies

Endocrine dysfunction is a frequent and often permanent complication of treatment. The research showed that 39% of patients had hormonal deficits before surgery. Following intervention, 40% developed permanent hypothyroidism. Additionally, 33% suffered from adrenal insufficiency, and 19% developed arginine vasopressin deficiency. Consequently, a multidisciplinary approach involving endocrinologists is vital for long-term care. These high rates of morbidity highlight the need for individualized treatment algorithms that prioritize quality of life.

Clinical FAQs

What are the primary predictors of tumor recurrence in ACP?

The extent of surgical resection is the most critical predictor. Subtotal resection and larger tumor volumes significantly increase the risk of disease progression over time.

How does the surgical approach impact outcomes in ACP?

Most modern centers prefer endoscopic transsphenoidal surgery, which was used in 76% of cases. While approaches vary, the primary goal remains achieving the maximal safe resection to improve survival.

What endocrine issues are common after ACP surgery?

Postoperative endocrinopathy is highly prevalent. Common issues include permanent hypothyroidism, adrenal insufficiency, and arginine vasopressin deficiency, requiring lifelong hormone replacement therapy.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

Shinya Y et al. Adamantinomatous craniopharyngioma: outcomes from a US multicenter registry cohort (RAPID consortium study). J Neurosurg. 2026 May 01. doi: 10.3171/2025.12.JNS252065. PMID: 42066361.

Catalino MP, et al. Early Findings from the Multicenter RAPID Consortium on Papillary Craniopharyngiomas. J Neurol Surg B Skull Base. 2024.

Müller HL. The Diagnosis and Management of Craniopharyngioma in Adults and Children. Front Endocrinol (Lausanne). 2020;11:433. doi: 10.3389/fendo.2020.00433.